Cyclic peptides cross lipid membranes by switching between an open, water-solvated conformation and a closed form that hides its polar backbone behind intramolecular hydrogen bonds. Molecular dynamics simulations trace this chameleon switch through four steps: anchoring, insertion, folding, and…
Cyclic peptides cross cell membranes by switching between two shapes. In water they open up, presenting polar backbone atoms to the solvent. In the non-polar environment of a lipid bilayer they close, folding those same atoms behind a network of intramolecular hydrogen bonds. Molecular dynamics simulations now trace this chameleon switch through four discrete steps, from the first contact of a side chain with the membrane surface to the final flip that carries the peptide to the far leaflet. For drug designers the message is practical: the permeable shape is not a fixed property of the molecule, it is a state the molecule adopts, and it can be engineered.
The two barriers that keep most peptides off the pill shelf are enzymatic degradation and membrane permeation. The second is the one that has resisted design rules. A peptide's backbone is packed with hydrogen-bond donors and acceptors, and every one of them must be paid for in desolvation energy before the molecule can enter lipid. The chameleon mechanism is how some cyclic peptides avoid that bill.
Peptide drugs are rarely given by mouth. Two barriers explain most of the failure. The first is enzymatic: the gut and the liver hydrolyze peptide bonds, and a linear peptide rarely survives transit intact. The second is the membrane itself. The intestinal epithelium, and the plasma membranes of target cells beyond it, separate the drug from the compartment where it must act, and a polar backbone does not partition readily into lipid.
The most instructive counterexample is cyclosporine A, a natural cyclic peptide that reached clinical use as an oral formulation. The year 1983 is widely cited as the breakthrough in oral delivery of peptides via cyclosporine A, which showed high oral bioavailability for a molecule of its size. The structure of cyclosporine A, shown in Figure 1 of the 2023 simulation study at the center of this article, remains the classic demonstration that a cyclic peptide can present a non-polar surface to a membrane while staying soluble enough in water to be absorbed.
The exception, however, did not become a rule. The success of oral cyclosporine A stimulated research enthusiasm, but the key to broadly opening the door to oral peptides has not been completely demonstrated, and the general problem remains unsolved. Most peptides in development are still injected. Stability can be purchased through cyclization, which generally improves both binding affinity and resistance to degradation, although not invariably PMID 22917248 . Permeability has proven far harder to predict, and it is the property the chameleon model directly addresses.
Linear peptides are too flexible for this mechanism. A linear chain exposes backbone carbonyl and amide groups that must be solvated, and it has no structural constraint that would allow it to fold those groups away on demand. Cyclic peptides are different. Closing the ring removes the flexible termini and limits the backbone to a smaller set of accessible conformations, and some cyclic peptides exploit that constraint to act as chameleons: they change conformation in response to the polarity of their surroundings PMID 36762908 .
The underlying chemistry is hydrogen bonding. In a polar environment, water competes for the backbone's hydrogen-bond donors and acceptors, and the peptide tends to adopt an open conformation in which these atoms are exposed to the solvent. In a non-polar environment there is no water to satisfy those bonds, so the peptide switches to a closed conformation in which the backbone forms intramolecular hydrogen bonds that shield its own polar groups. The chameleon switch is therefore a conversion between intermolecular hydrogen bonds to water and intramolecular hydrogen bonds within the peptide.
The consequences are quantifiable. The closed conformation reduces the polar surface area of the molecule and lowers its desolvation energy, shifting the balance between water and lipid solubility in favor of the membrane. That is what allows one molecule to be water-soluble enough to reach a bilayer and lipophilic enough to enter it. In this framework the closed state is generally regarded as the main permeable state, and the equilibrium between open and closed is dynamic. It depends on the amino acid sequence, on molecular size, and on the extent of the hydrophobic surface, and it runs in both directions: a peptide that is closed at the membrane surface can reopen once it reaches the aqueous compartment on the far side.
The structure of the flexible decacyclic peptide used in the simulation appears in Figure 2 of the 2023 study. It was chosen precisely because its backbone flexibility permits the kind of switching described above. Which conformation dominates before the peptide meets a membrane, and which residues are exposed in that conformation, are the inputs a designer needs to predict membrane behavior.
The most detailed account of the mechanism comes from molecular dynamics simulations by Stephanie M. Linker and colleagues at ETH Zurich, published in the Journal of Medicinal Chemistry in 2023 66 4 :2773-2788, PMID 36762908 . The study simulated the interaction of a flexible decacyclic peptide with a model lipid bilayer, and Figure 3 of the paper diagrams the pathway. The simulations produced a four-step sequence for passive membrane crossing.
| Step | Event | What the simulation shows |
| --- | --- | --- |
| 1 | Side-chain anchoring | Specific amino acid side chains make the first contact with the membrane before the ring inserts |
| 2 | Insertion at the interface | The peptide inserts at the boundary between polar head groups and non-polar tails, lying parallel to the membrane plane |
| 3 | Open-to-closed transition | The peptide folds from its open to its closed conformation inside the membrane, a step required for diffusion |
| 4 | Diffusion and flipping | The closed peptide crosses the non-polar core, anchors to the lower leaflet, and flips to complete passage |
The first step is anchoring. Certain side chains act as molecular anchors , establishing the initial contact with the membrane. These anchors are not fixed properties of specific residues; the simulated anchor residues differed between the open and closed conformations of the peptide, because the residues that contact the membrane depend on the shape the molecule is in. Knowing which residues are exposed in the dominant pre-membrane conformation gives some idea of which side chains will touch the bilayer first.
The second step is insertion. The peptide inserts at the interface between the polar head groups and the non-polar fatty-acid tails, lying parallel to the plane of the membrane. Here the simulation found a bifurcation. An open-state peptide could take either of two orientations, termed A and B, and orientation A was preferred. A closed, pre-folded peptide took only orientation B. The distinction matters because only orientation B favors the open-to-closed transition, the step on which everything downstream depends. This is the origin of the design suggestion that macrocyclic peptides with continuous hydrophobic surfaces are more likely to enter the membrane in the productive orientation.
The third step is the conformational transition. Movement from the open to the closed state inside the membrane increases the chance that the peptide will penetrate deeper, and it is crucial for diffusion within the bilayer. Open-state molecules, the simulations indicated, have difficulty diffusing through the lipid environment because their exposed polar groups are costly to bury. The closed state, with its intramolecular hydrogen bonds and diminished polar surface area, is the form that can move.
The fourth step is the crossing itself. Only closed-state peptides could diffuse through the non-polar lipid core to the opposite polar/non-polar interface. Completion required anchoring to the lower leaflet and a flip of the peptide, an event that changes the direction of the hydrophobic moment . The flip reorients the molecule so its polar face can exit into the aqueous compartment on the far side. The study's own conclusion frames the whole pathway as a design tool: understanding the conformations and exposed residues of a cyclic peptide before membrane entry can improve the rational design of membrane-permeable cyclic peptides. The stated goal of the work is to improve peptide bioavailability, especially oral bioavailability, and to enable more orally deliverable peptide drugs.
The pathway suggests concrete practices, each of which still needs empirical confirmation for the particular molecule in hand.
First, characterize the conformational ensemble before touching a membrane. The conformations a cyclic peptide adopts in aqueous solution, and the residues exposed in each, determine which side chains will anchor and which orientation the ring takes at the interface. Solution NMR or computational conformational sampling can supply this information before synthesis. Docking tools for flexible cyclic peptides already exist: AutoDock CrankPep identified the correct interaction geometry in 71% of 38 cyclic peptide complexes within its top 10 predicted solutions PMID 31505931 , making it a plausible screening step in a design loop.
Second, engineer the anchors. Because side-chain contact with the membrane is the first event in the pathway, placing residues at positions exposed in the dominant solution conformation can promote initial membrane contact. The same logic may extend beyond peptides: the authors suggest that moderate conjugation of aliphatic chains can increase membrane permeability in other molecule classes by supplying an anchoring function. That extrapolation is speculative and needs its own test.
Third, design for orientation B. Since only one of the two insertion orientations permits the open-to-closed transition, the goal is a macrocycle whose surface properties favor that orientation. The simulation-based implication is that continuous hydrophobic surfaces encourage productive insertion. It is a hypothesis, not a validated rule, but it is testable.
Fourth, balance the surface. A molecule too polar will never partition into the membrane; one too lipophilic will be insoluble in water and poorly absorbed regardless of permeability. The chameleon mechanism works because the same molecule can present a polar face in water and a non-polar face in lipid, so the design task is to preserve both faces rather than maximize either.
Fifth, treat individual residues as context-dependent. The simulations showed that the contributions of leucine, phenylalanine, and proline to permeation depended heavily on their position in the peptide and on the surrounding sequence. There is no portable permeability scale for single amino acids; the same residue can help or hinder depending on its neighbors. The broader literature agrees that cyclization effects are not uniform: a comparative review of linear and cyclic cancer-targeting peptides found that cyclization generally improves binding affinity and stability, but in some cases linear analogues are superior PMID 22917248 .
The four-step pathway is a product of molecular dynamics simulation, not of direct observation. No experiment has yet imaged a cyclic peptide performing all four steps in a living membrane. The simulation's strengths are its internal consistency and its agreement with the known physicochemical requirements of permeation: it explains why open-state molecules stall at the interface, why the closed state is the diffusible form, and why the hydrophobic-moment flip is necessary to exit on the far side. Agreement with expectation, however, is not proof.
Circumstantial support comes from other cyclic peptide systems. A cyclic octapeptide that assembles into nanotubes showed ice recrystallization inhibition activity only at low pH, because bundling at higher pH masked the active sites PMID 35045706 . The phenomenon is not membrane permeation, but it demonstrates empirically that the conformation and surface presentation of a cyclic peptide can shift sharply with environmental conditions, exactly the kind of switching the chameleon model proposes.
The chemical space in which these rules would operate is also much larger than the handful of drug-like examples suggests. A genome-mining study identified 11 previously unknown P450-modified ribosomally synthesized peptides with diverse cross-linking patterns across four classes PMID 38069901 . That structural diversity is a warning: permeability rules derived from one flexible decacyclic peptide may or may not transfer to other ring sizes, cross-link patterns, and sequences. Some macrocycles will behave as chameleons; others will not.
What the record does not yet show is a validated design method. No prospective study has used the chameleon logic to design a series of cyclic peptides, predicted their permeability in silico, and confirmed the predictions across a membrane in vitro or in vivo. Oral cyclosporine A remains the existence proof that the route works; the simulations provide a mechanistic explanation of how it might work; the gap between those two is a demand for experiments, not a license to assume the rules are settled.
The central caveat is provenance. The four-step pathway comes from a single simulation study of a single decacyclic peptide. It is not a general law, and the study does not claim it is. The open/closed equilibrium is dynamic and depends on sequence, size, and hydrophobic surface area, all of which vary enormously across macrocyclic peptide space. Whether the four steps are universal for flexible cyclic peptides or specific to rings of this type is unknown.
Several questions follow directly. What design rules reliably control whether a cyclic peptide is open or closed before and during membrane interaction? The simulations identify the factors that matter, sequence, size, hydrophobic surface, but they do not provide quantitative cutoffs that would let a chemist predict the equilibrium constant from structure. Can the anchoring, insertion, and flipping steps be confirmed experimentally in living cells or model membranes? Techniques such as surface plasmon resonance, neutron reflectometry, and single-molecule fluorescence could in principle observe parts of the pathway, but no such study has yet been reported. Can chameleon behavior be engineered without sacrificing target binding affinity or metabolic stability? The same backbone that folds away in a membrane also presents the binding surface to a target protein, and the two requirements can conflict. And is the anchor strategy transferable to other therapeutic modalities without introducing toxicity? Increased membrane permeability in off-target tissues is a genuine risk for any molecule engineered to cross membranes more freely.
The largest open question is the one the field has carried since 1983. Cyclosporine A proved that an oral cyclic peptide drug is possible. The general problem of designing orally bioavailable peptides has not been solved. What the chameleon mechanism provides is a mechanistic frame: a molecule must be able to present two faces, switch between them at the right place, and do so without losing the activity that makes it a drug. That is a design target. It is not yet a design method.
Related reading: Five Enzymatic Routes to Oligopeptides and Short Peptide Synthesis, Neoantigen Peptide Synthesis Services and GMP Manufacturing, Enzyme classes for biocatalytic synthesis of short oligopeptides, Choosing Coupling Reagents for Solid-Phase Peptide Synthesis.